精神分裂症患者血清S100B蛋白检测的临床意义  

Clinical significance of the determining of serum S100B protein in patients with schizophrenia

作　　者：纪家武[1] 陈永聪[2] 林力[1] 陈红岩[1] 黄少雅[1] 翁赛铮[1] 林瑞前[1] 郭少楠[1] 黄炜静[1] 

机构地区：[1]福州市第四医院,350008 [2]福建省农科院生物技术研究所

出　　处：《福建医药杂志》2008年第6期89-91,共3页Fujian Medical Journal

摘　　要：目的探讨精神分裂症患者血清S100B蛋白检测的临床意义。方法采用ELISA法测定29例精神分裂症首发病人(首发组)治疗前及治疗12周的血清S100B蛋白。30例体检合格者为正常对照组,20例慢性精神分裂症患者为慢性对照组。于治疗前、治疗12周时,以阳性与阴性症状量表(PANSS)评定各组病人精神症状。结果首发患者治疗前S100B与PANSS总分和各因子分均无显著相关(r均<0.357,P>0.05);治疗后及慢性组S100B浓度与PANSS阴性因子分呈显著相关(r均>0.374,P<0.05);首发组治疗前、后与慢性组、对照组之间血清S100B水平差异无统计学意义(F=2.174,P>0.05)。结论血清S100B蛋白检测不宜作为精神分裂症患者病情变化的指标。Objective To explore the clinical significance of the determining of the serum S100B protein concentration in patients with schizophrenia.Methods The serum S100B proteins of 29 first episode patients with schizophrenia were measured by Enzyme-linked-immunoabsorbent assay(ELISA)before and after 12 weeks medicine treatment.Thirty serum samples of qualified physical examination persons(normal controls)and 20 serum samples of chronic inpatients with schizophrenia(chronic controls)were measured by the same way.T...

关 键 词：精神分裂症 S100B蛋白 ELISA 

分 类 号：R749.3[医药卫生—神经病学与精神病学]